We previously demonstrated that patients with metastatic KRAS mutant lung cancers have a shorter survival compared with patients with KRAS wild-type cancers. Recent reports have suggested different clinical outcomes and distinct activated signaling pathways depending on KRAS mutation subtype. To better understand the impact of KRAS mutation subtype, we analyzed data from 677 patients with KRAS mutant metastatic lung cancer.
R
AS mutations are identified in 25%-30% of lung adenocarcinomas; the vast majority is KRAS mutations occurring at codon 12 or 13. In small cohorts, specific point mutations such as G12V and G12R and KRAS codon 12 have been associated with trends toward poorer outcomes. [1] [2] [3] It is difficult to make definitive conclusions about KRAS mutations as a prognostic marker as published studies use differing molecular diagnostic techniques, comparing populations and endpoints. [1] [2] [3] [4] [5] [6] [7] [8] [9] Moreover, the discovery of other oncogenes such as epidermal growth factor receptor (EGFR) and ALK with potent targeted therapy available 10, 11 must be taken into account when evaluating the prognostic significance of any biomarker as these discoveries highlight the heterogeneity of the KRAS wild-type designation.
Studies report superior survival for never-smokers compared with current or ex-smokers, 12 which may be due to a differing distribution of oncogenic drivers with KRAS more frequent in smokers and EGFR and ALK alterations more common in never smokers. 13 There are no differences in survival between current/former smokers and never smokers when their tumors harbor the same driver oncogene. 13 Transversion mutations refer to the substitution of a purine nucleotide to a pyrimidine, or vice versa. Transitions refer to a purine to purine or pyrimidine to pyrimidine nucleotide change. Within KRAS, transversion mutations are more common in current or ex-smokers, and never-smokers have a higher frequency of transition mutations. 14, 15 Data with regard to outcomes for KRAS transition versus transversion mutations are conflicting. 2, 16 In colorectal cancer, the specific KRAS point mutation present may be a prognostic and predictive marker with G12V conveying an increased risk of disease recurrence and death. [17] [18] [19] Patients with KRAS codon 12 mutant colorectal tumors had shorter overall survival compared with patients with KRAS codon 13 mutant tumors. 19 The biologic basis of these findings is not fully understood but may be related to differences in downstream signaling or protein expression. 20, 21 In colorectal cancer, KRAS mutation status has been validated as a predictive marker of response to EGFR-targeted therapies with the presence of a KRAS mutation predicting a lack of response to cetuximab or panitumumab, 22 and newer data raise the possibility that specific KRAS point mutations may induce differential responses to EGFR-directed therapies. 23 In lung cancers, the predictive utility of KRAS mutations as a marker of response to both targeted therapy and standard cytotoxic chemotherapy has been of great interest (Table 1) . The presence of a KRAS mutation suggests a lack of response to EGFR tyrosine kinase inhibitors, 24, 25 but has not been helpful in selecting patients for treatment with EGFR monoclonal antibodies. 26, 27 In the BATTLE trial, patients with KRAS G12C and G12V mutant lung cancers were found to have a shorter progression-free survival than other KRAS genotypes with certain targeted therapies such as erlotinib, vandetanib, bexarotene, and sorafenib. 28 Recent data suggest that the specific KRAS mutation present may predict response to adjuvant chemotherapy RT, radiotherapy; EGFR, epidermal growth factor receptor; NSCLC, non-small-cell lung cancer; HR, hazard ratio; CI, confidence interval; OS, overall survival; PFS, progressionfree survival.
for patients with resected non-small-cell lung cancer. Patients harboring KRAS codon 13 mutations appear to have poorer outcomes with adjuvant cisplatin-based chemotherapy. 29 In the metastatic setting, KRAS mutations do not appear to independently predict response or resistance to chemotherapy treatments. [30] [31] [32] [33] We hypothesized that with a large number of patients with KRAS mutant advanced lung cancers, we would have sufficient power to identify any clinically meaningful differences in outcome related to specific KRAS mutation subtypes. To evaluate this hypothesis, we reviewed specific KRAS point mutation status, clinical characteristics and survival of patients with metastatic KRAS mutant lung cancers identified at our institution and then evaluated key findings in an independent group of patients from other institutions.
METHODS

Patients
Consecutive patients with metastatic or recurrent lung cancers found to have a KRAS-mutation by routine molecular testing performed between January 2005 and January 2011 were included in this analysis. An electronic medical record search was used to identify individuals seen at Memorial Sloan-Kettering with a primary tumor diagnosis of lung cancer by ICD-0 code with available diagnostic molecular pathology reports that indicated the presence of a KRAS mutation. The list was then manually reviewed to exclude patients who did not have metastatic or recurrent disease or a tumor diagnosis of a primary lung cancer. Data collection was approved by the MSKCC Institutional Review Board/Privacy Board. We collected clinical characteristics and treatment course for all patients. Overall survival was defined as the time from date of advanced disease (stage IV or recurrent) until date of death or last follow-up. KRAS mutation analysis was performed before this retrospective review on available tissue by standard Sanger sequencing or by a mass spectrometry based mutation profiling assay. 34, 35 Information on mutation status and outcomes for patients with stage IV KRAS-mutant lung cancers identified by routine molecular sequencing during the same time period were collected from Dana Farber Cancer Institute, Massachusetts General Hospital Cancer Center, and Vanderbilt Ingram Cancer Center. This dataset was compiled with the intent to verify any significant findings in our institutional dataset.
Statistical Methods
We compared characteristics of patients with KRAS codon 12 and codon 13 mutant tumors using t test (for continuous variables) and χ 2 test (for categorical variables). Overall survival following diagnosis of stage IV lung cancer was estimated using Kaplan-Meier methodology. Patients were followed until death; patients alive at the end of the study were censored at the time of the last available follow-up. Univariate group comparisons were performed using log-rank tests. A multivariate Cox proportional hazards model was used to assess the independent effect of KRAS mutation type, controlling for potential confounding factors associated with overall survival in univariate analysis. All associations found significant were validated using the external validation set.
RESULTS
Clinical Characteristics
We evaluated tumor specimens from 3357 unique patients with lung cancers for KRAS mutations. During that period, 677 patients were identified to have metastatic lung cancer that harbored a KRAS mutation. Patient demographics are noted in Table 2 . The majority (59%) had chemotherapy treatment details available. Of those with available data, there was no difference in the frequency of platinum-based chemotherapy, pemetrexed and/or bevacizumab among patients with KRAS codon 12 versus codon 13 mutations. The median line of treatment in those who received chemotherapy at MSKCC was 2 (range 1-9).
KRAS Mutation Subtype
The most frequent nucleotide change in tumor specimens was a guanine to thymidine (G>T) seen in 366 patients. The prevalence of specific KRAS point mutations is summarized in Figure 1 . Mutations were found at codon 12 in 624 patients (92%), and codon 13 in 53 patients (8%). Twentythree percent of patients (157 of 677) had transition mutations (G12D, G12S, G13D, G13S). The prevalence of specific point mutations differed between former/current smokers and never-smokers (Fig. 1) . Patients with transition mutations were more likely to be never-smokers, compared with patients with transversion mutations (p < 0.001). Clinical characteristics were similar between patients with KRAS codon 12 versus 13 mutations (Table 2) . No concurrent EGFR mutations or ALK rearrangements were found in any patients.
KRAS Mutation and Survival
The median follow-up among 197 patients alive at the data cutoff of June 2012 was 17 months (range 1-207 months). The median overall survival for all patients with KRAS mutant advanced lung cancers in our cohort was 1.2 years (95% confidence interval [CI]: 1.2-1.4 years). Median overall survival for specific KRAS point mutations ranged from 0.7 years (G13C) to 1.5 years (G12F), although no significant (Fig. 2) . There was no difference in outcome for patients with KRAS transition versus transversion mutations, with a median survival of 1.2 years for both (p = 0.66) (Fig. 3A) . No difference in overall survival was seen in patients with KRAS mutant lung cancers who are current or former-smokers (n = 625) compared with never-smokers (n = 48), median overall survival 1. 
Multivariate Analysis
We evaluated sex, age, smoking history, and KRAS codon to determine impact on survival (Table 3) . Sex, age, and KRAS codon were associated with survival in univariate analysis. Men had increased risk of death, compared with that of women (hazard ratio [HR]: 1.28, 95% CI: 1.07-1.55; p = 0.008). Older age was significantly associated with increased risk of death, with each five additional years at diagnosis increasing the risk of death by 5% (HR: 1.05 for each added years, 95% CI: 1.01-1.10; p = 0.026). Smoking history did not affect outcome among those with KRAS mutations (HR: 1.2, 95% CI: 0.83-1.72; p = 0.34). KRAS codon was associated with overall survival, with KRAS codon 13 mutant tumors having an increased risk of death, compared with patients with KRAS codon 12 (HR: 1.50, 95% CI: 1.11-2.04; p = 0.009). In a multivariate analysis controlling for age, sex, and smoking history, KRAS codon 13 was associated with shorter overall survival (HR: 1.52, 95% CI: 1.11-2.08; p = 0.008; Table 3 ).
External Validation Set
To verify the survival difference in patients with KRAS codon 13 versus codon 12 mutant lung cancer, we used an external validation set consisting of patients with KRAS mutant lung cancers treated at other institutions (Table 4 ). In total, 682 patients were analyzed: 354 patients from Dana Farber Cancer Institute, 242 patients from Massachusetts General Hospital, and 86 patients from Vanderbilt Ingram Cancer Center. In this collected set, there was no difference in overall survival from time of advanced disease in patients with KRAS codon 13 versus codon 12 mutant metastatic lung cancers, 1 year (95% CI: 0.7-1.5 years) versus 1.1 year (95% CI: 0.9-1.2 years), respectively (Fig. 4) . Median follow-up was similar in our dataset and the validation dataset. Median overall survival was longer in our dataset compared with the validation set, 15 versus 13 months, respectively (p = 0.05). 
DISCUSSION
In this series of patients, the largest reported series of patients with KRAS mutant lung cancers, we validated clinical prognostic factors known to be relevant in advanced lung cancers, but did not observe any difference in outcomes based on individual KRAS genotype (specific point mutation, transition versus transversion, G12 versus 13). Although others have noted that the specific KRAS point mutations present is associated with outcomes in smaller series, 2 such differences were not observed in our group of patients. The importance of independent validation of observed prognostic differences is underscored by our identification of a difference in outcomes for KRAS G13 versus G12, which was not confirmed in a cohort of similar patients seen at three other cancer centers.
Similar to our findings, Shepherd et al. 29 found that KRAS mutation was not prognostic in patients with early stage lung cancer. Other factors besides mutation subtype might be influencing survival. The presence of concurrent mutations may also influence the clinical phenotype seen with different KRAS mutation subtypes. LKB1 (STK11) and p53 mutations are seen concurrently with KRAS mutations and portend a poorer prognosis in patients, although the prevalence of concurrent mutations has only been assessed in small series. [36] [37] [38] [39] [40] Preclinical data indicate that loss of LKB1 leads to a more aggressive tumor phenotype, with short tumor latency and greater rate of metastasis. 37 The presence of concurrent mutations may also have treatment implications as preclinical data suggest concurrent LKB1 inactivation alters downstream signaling and sensitivity to mammalian target of rapamycin and MEK inhibition. [41] [42] [43] More clearly characterizing the frequency of concurrent mutations and understanding their correlation with clinical behavior will be helpful in further defining the prognosis of patients with KRAS mutant lung cancers.
There are limitations to our analysis. All patients were identified based upon molecular testing at a single institution during a time (beginning in 2005) in which molecular analysis was not broadly performed, and therefore these patients may not be representative of a general population. They received diverse treatment and the vast majority did not receive any KRAS-directed targeted therapy. Patients with different KRAS mutation subtypes may respond differently to chemotherapy, and our analysis was not powered to identify any predictive effects of KRAS mutation subtype. Performance status, a powerful prognostic factor, was not included in our analysis. In addition, even with a larger dataset, we are limited in our ability to make conclusions regarding KRAS mutation subsets that are rare. Due to these limitations, we attempted to validate our findings in an external dataset, in which we did not find a difference in survival when comparing patients with KRAS G12 versus G13 mutant tumors. Further validation would be needed to draw definitive conclusions regarding the prognostic value of KRAS mutation subtype.
KRAS mutation subtype does not appear to be associated with overall survival from the diagnosis of lung cancer. Investigation into other areas such as variable gene expression and identifying concurrent mutations may identify potential molecular prognostic markers in patients with KRAS mutant lung cancers. 
